Ozempic price in Spain: how much it costs per pen and per month in 2026

If you are looking up the price of Ozempic in Spain, the short answer is that not every pen costs the same and that the monthly cost depends on the presentation. It is also worth separating two issues: its retail price and its funding status, which in Spain is restricted.

What is the price of an Ozempic pen in Spain in 2026

As of September 2026, the retail price including VAT of Ozempic in Spain is €117.89 for the 0.25 mg, 0.5 mg and 1 mg presentations with 4 doses. The 1 mg presentation with 8 doses costs €204.83. The 2 mg presentation is not listed as marketed in the AEMPS register and does not appear in the Nomenclátor, so it currently has no published pharmacy price.

Put simply, talking about “the price of an Ozempic pen” can be misleading, because it depends on how many doses that presentation contains and on the strength involved. The product documentation itself also states that not all pack sizes may be marketed.

How much Ozempic costs per month

Since a pen with 4 weekly doses is in practice equivalent to about 4 weeks of treatment, the approximate cost per 4 weeks is €117.89 for the 0.25 mg, 0.5 mg and 1 mg presentations when a 4-dose pen is used.

There is one important exception: the 1 mg presentation with 8 doses costs €204.83 and covers 8 weeks, which works out at about €102.42 per 4 weeks. That is why it is not correct to say that the monthly cost is always €117.89.

If you want to understand where this medicine sits within its class, it may help to read GLP-1: what they are, how they work and why they are transforming the treatment of obesity. And if you are looking for the regulatory context and how this brand is used, there is a broader guide in Ozempic in Spain: what it is, how it works and who can take it.

Is Ozempic funded in Spain

Yes, but on a restricted basis. Ozempic is funded by the Spanish National Health System with prior authorisation (visado) for certain patients with type 2 diabetes mellitus, people with obesity with a BMI ≥30 kg/m² and on combination therapy with other diabetes medicines; monotherapy is not included.

This does not mean it is funded for weight loss as a general use, nor that anyone can obtain it with public cover. It is also worth remembering that Ozempic is authorised in Spain for adults with type 2 diabetes mellitus as an adjunct to diet and exercise. The semaglutide brand authorised specifically for weight management is Wegovy.

In people with related metabolic disorders, the conversation often overlaps with topics such as prediabetes and how it is managed or metabolic syndrome and why it develops, because the clinical context matters more than looking at the price alone.

What is known about its efficacy according to the Spanish summary of product characteristics

The Spanish summary of product characteristics records that the efficacy and safety of once-weekly semaglutide 0.5 mg and 1 mg were assessed in 6 randomised, controlled phase 3a clinical trials involving 7,215 patients with type 2 diabetes, of whom 4,107 received semaglutide.

In addition, compared with placebo, the summary of product characteristics reports relative reductions of 22% in fasting glucose and 37% in 2-hour postprandial glucose in certain pharmacodynamic analyses. These data help explain why the medicine has a clinical role in type 2 diabetes, although on their own they do not answer the question of how much it costs or whether it is funded in each case.

The key point, in one sentence

The key idea is simple: the price of Ozempic in Spain in 2026 varies by presentation, and public funding exists only in specific situations, not as general access for weight loss. If what you are really looking for is guidance on whether medical treatment for weight loss or metabolic health suits your case, in Spain today that involves a prior assessment, a prescription where appropriate from a registered doctor and ongoing follow-up. You can check in a few minutes whether you are eligible.